FY2024 EPS Estimates for Intelligent Bio Solutions Inc. Increased by Analyst (NASDAQ:INBS)

Intelligent Bio Solutions Inc. (NASDAQ:INBS) – Equities research analysts at Zacks Small Cap raised their FY2024 earnings estimates for shares of Intelligent Bio Solutions in a research note issued on Wednesday, November 15th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($1.01) per share for the year, up from their previous estimate of ($4.56). The consensus estimate for Intelligent Bio Solutions’ current full-year earnings is ($3.44) per share. Zacks Small Cap also issued estimates for Intelligent Bio Solutions’ FY2025 earnings at ($0.47) EPS.

Intelligent Bio Solutions (NASDAQ:INBS) last posted its quarterly earnings data on Thursday, August 24th. The company reported ($1.91) EPS for the quarter, missing the consensus estimate of ($1.66) by ($0.25). Intelligent Bio Solutions had a negative return on equity of 147.23% and a negative net margin of 510.29%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $0.49 million.

Intelligent Bio Solutions Stock Performance

Shares of INBS opened at $0.45 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.25 and a current ratio of 0.39. The stock has a 50-day moving average of $0.63 and a two-hundred day moving average of $1.83. The stock has a market cap of $3.96 million, a P/E ratio of -0.05 and a beta of 4.03. Intelligent Bio Solutions has a one year low of $0.20 and a one year high of $32.00.

Hedge Funds Weigh In On Intelligent Bio Solutions

A hedge fund recently bought a new stake in Intelligent Bio Solutions stock. Sabby Management LLC bought a new position in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 126,650 shares of the company’s stock, valued at approximately $367,000. Intelligent Bio Solutions comprises approximately 0.3% of Sabby Management LLC’s investment portfolio, making the stock its 26th largest holding. Sabby Management LLC owned approximately 8.52% of Intelligent Bio Solutions as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 9.28% of the company’s stock.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.